Identification and characterization of a novel melanoma tumor suppressor gene on human chromosome 6q21

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 797-803

  Fung, Jackie Mei Wah ^a   Smith, Ross ^b   Brown, Melissa A ^b   Lau, Sze Hang ^a   Xie, Dan ^a   Lau, George K ^a   Guan, Xin Yuan ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CHROMOSOME 6Q; CHROMOSOME REARRANGEMENT; COLONY FORMING UNIT; CONTROLLED STUDY; DNA LIBRARY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC SCREENING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MOLECULAR PROBE; MOUSE; NEVUS; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRENYLDIPHOSPHATE SYNTHASE SUBUNIT 2 GENE; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

EID: 61349098014     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1472     Document Type: Article

References (36)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.
2. Thompson FH, Emerson J, Olson S, et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyo-types. Cancer Genet Cytogenet 1995;83:93-104.
3. van Gils W, Kilic E, Bruggenwirth HT, et al. Regional deletion and amplification on chromosome 6 in a uveal melanoma case without abnormalities on chromo-somes 1p, 3 and 8. Melanoma Res 2008;18:10-5.
4. Mensink HW, Kilic E, Vaarwater J,et al. Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome. Cancer Genet Cytogenet 2008;181:108-11.
5. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 1990; 247:568-71.
6. Taborelli M,Tibiletti MG, Martin V, et al. Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genet Cytogenet 2006;165:106-13.
7. Hoglund M, Gisselsson D, Hansen GB, et al. Ovarian carcinoma develops through multiple modes of chromosomal evolution. Cancer Res 2003;63:3378-85.
8. Konishi N,Nakamura M,Kishi M, et al. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci 2003;94: 764-8.
9. Guan XY, Zhang HE, Zhou H, et al. Characterization of a complex chromosome rearrangement involving 6q in a melanoma cell line by chromosome microdissection. Cancer Genet Cytogenet 2002;134:65-70.
10. Ray ME,Wistow G, Su YA, et al. AlM1, a novel non- lens member of the βγ-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci U S A 1997;94: 3229-34.
11. Church SL, Grant JW, Ridnour LA, et al. lncreased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci U S A 1993;90:3113-7.
12. Miele ME, McGary CT,Welch DR. SOD2 (MnSOD) does not suppress tumorigenicity or metastasis of human melanoma C8161 cells. Anticancer Res 1995;15: 2065-70.
13. Saiki R, Nagata A, Kainou T, et al. Characterization of solanesyl and decaprenyl diphosphate synthases in mice and humans. FEBS J 2005;272:5606-22.
14. Lòpez LC, Schuelke M, Quinzii CM. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006;79:1125-9.
15. Xie D, Sham JS, Zeng WF, et al. Heterogeneous expression and association of β-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. lnt J Cancer 2003;107:896-902.
16. Quinzii CM, Di Mauro S,Hirano M. Human coenzyme Q10 deficiency. Neurochem Res 2007;32: 723-7.
17. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660:171-99.
18. Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. Mitochondrion 2007;7:S41-50.
19. Mollet J, Giurgea l, Schlemmer D, et al. Prenyldi-phosphate synthase, subunit1 (PDSS1) andOH-ben-zoate polyprenyl transferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin lnvest 2007;117:765-72.
20. Picardo M, Grammatico P, Roccella F, et al. lmbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J lnvest Dermatol 1996;107:322-6.
21. Portakal O, Ozkaya O, Erden lnal M, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33: 279-84.
22. Quinzii C, Lopez L, Von-Moltke J, et al. Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency. FASEB J 2008; 22:1-22.
23. Folkers K. The potential of coenzyme Q 10 (NSC-140865) in cancer treatment. Cancer Chemother Rep 2 1974;4:19-22.
24. Baggio E, Gandini R,Plancher AC, et al. ltalian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance lnvestigators. Mol Aspects Med 1994;15 Suppl:s 287-94.
25. Cortes EP, Gupta M, Chou C, et al. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 1978;62:887-91.
26. Folkers K, Shizukuishi S,Takemura K, et al. lncrease in levels of lgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1982;38:335-8.
27. Tomasetti M, Alleva R, Borghi B, et al. In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J 2001;15:1425-7.
28. Quiles JL, Farquharson AJ, Ramirez-Tortosa MC, et al. Coenzyme Q differentially modulates phospholipid hydroperoxide glutathione peroxidase gene expression and free radicals production in malignant and non-malignant prostate cells. Biofactors 2003;18: 265-70.
29. Kawase l, Niitani H, Saijo N, et al. Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice. Gann 1978;69:493-7.
30. Folkers K, Porter TH, Bertino JR, et al. lnhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. Res Commun Chem Pathol Pharmacol 1978;19:485-90.
31. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
32. Kaghad M, Bonnet H,Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
33. Okamoto A, Hussain SP, Hagiwara K, et al. Mutations in the p16lNK4/MTS1/CDKN2, p15lNK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995;55:1448-51.
34. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 2004;1654: 105-22.
35. Peng M, Falk M, Haase V, et al. Primary coenzyme Q deficiencyin Pdss2 mutant mice causes isolated renal disease. PLoS Genet 2008;4:1-14.
36. Guan XY, Zhang H, Yang JM, et al. Detection of chromosome 6 abnormalities in melanoma cell lines by chromosome arm painting probes. Cancer Genet Cytogenet 1998;107:89-92.